pulmonx
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
700 Chesapeake Dr, Redwood City, Califor...Phone Number
(650) 364-0400Website
www.pulmonx.comRevenue
$87.4 MillionStock Symbol
LUNGIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About pulmonx
Pulmonx Corporation is a commercial-stage medical technology company focused on developing and commercializing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's flagship product, the Zephyr® Endobronchial Valve, is an FDA-approved implant designed to reduce lung hyperinflation by collapsing diseased portions of the lung, thereby improving breathing and quality of life for patients. Pulmonx also offers diagnostic and planning tools such as the Chartis® Pulmonary Assessment System and the StratX®/LungTraX® platforms, which help identify appropriate candidates for treatment through advanced lung imaging and functional assessment. With over 40,000 patients treated globally, Pulmonx is a leader in the interventional pulmonology space.Explore more
pulmonx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is pulmonx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if pulmonx had a recent Job posting/layoffs
Earning: See what the market has to say on pulmonx recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at pulmonx
pulmonx, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when pulmonx launches new products
Check if pulmonx has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if pulmonx is spiking on competitors!
Funding: Get notified immidiatlly once pulmonx has new funding data
Recommended Actions
Find VP level buyers at pulmonx
Find 2 more new buyers
Compare Similar Companies to pulmonx
Compare insights from companies similar to pulmonx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
pulmonx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
pulmonx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about pulmonx.
pulmonx financials insights
Gather financial insights about pulmonx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Series A
$7.1M
2007
Series B
$20M
2010
Series C
$32M
2012
Series D
$10M
2014
Private Equity
$10M
Debt
$20M
2015
Private Equity
$50M
2020
Multiple Rounds
$272M
pulmonx Tech Stack
A closer look at the technologies used by pulmonx
See more technologies
Most Recent Scoops
Open Position
Project
pulmonx has presented results from the Convert One trial demonstrating that Aeroseal converted approximately 75% of collateral ventilation-positive patients to collateral ventilation-negative status, enabling subsequent Zephyr valve placement and representing a total addressable market expansion opportunity.
Research & Development
Project
pulmonx has achieved inclusion of the Zephyr valve in the GOLD guidelines for COPD patients as a standard of care component, receiving the highest level of evidence designation.
Project
pulmonx has published results from four randomized controlled trials in the American Journal of Respiratory and Critical Care Medicine and the New England Journal of Medicine, each demonstrating statistically significant and clinically meaningful improvements in lung function, exercise capacity, and quality of life across all measured endpoints.
Medical Research
Left Company
Executive Move
pulmonx News & Media
Pulmonx Q2 Earnings Call Highlights
Pulmonx (NASDAQ:LUNG) reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China. Revenue for the quarterPulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to 17 individuals hired by Pulmonx in the first two quarters of 2026. The awards were approved by the Compensation Committee of the Company’s Board of
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding pulmonx
Sign Up For FreeTo access detailed company insights
Pulmonx Corporation is a commercial-stage medical technology company focused on developing and commercializing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's flagship product, the Zephyr® Endobronchial Valve, is an FDA-approved implant designed to reduce lung hyperinflation... Read More
